Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTRX-101
- Development stage
- Preclinical
- Lead developer
- CounterX Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
CTRX-101 is a long-acting monoclonal antibody therapy being developed by CounterX Therapeutics for the prevention and treatment of fentanyl overdose, particularly in high-risk patients with moderate to severe opioid use disorder (OUD). Unlike traditional overdose reversal agents like naloxone, which act as opioid receptor antagonists, CTRX-101 targets the fentanyl molecule itself. By sequestering fentanyl in the systemic circulation, the antibody prevents the drug from entering the central nervous system and causing life-threatening respiratory depression. Administered as a subcutaneous injectable, CTRX-101 is designed to provide sustained protection without precipitating opioid withdrawal. As of late 2024, the drug is in preclinical development with an Investigational New Drug (IND) application anticipated in late 2025.
- Other names
- chimeric HY6-F9humanized HY6-F9
Beyond the preview
Go deeper on CTRX-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTRX-101.